Corcept Therapeutics Q1 2026: Record Revenue, Oncology Success

Corcept Therapeutics Q1 2026 earnings show a revenue surge, with full-year guidance raised to $950M - $1.05B. Cushings syndrome meds hit records, and Lifyorli, approved for ovarian cancer, is launching strongly. The pipeline is robust, with relacorilant NDA talks, expanding oncology trials, and promising ALS drug results. Cushings revenue is projected to reach at least $2B annually by 2030, with Lifyorli topping $1B in the US, and cortisol modulation poised for significant gains across diseases. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2c057c026dff4fae